TRDA

+ Watchlist + Portfolio

Entrada Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.68
52-Week Range: $5.17 – $16.45
Market Cap: $209.48M
P/E (TTM): —
EPS (TTM): -3.96
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.83
PEG Ratio: —
Return on Equity: -54.10%
Return on Assets: -29.20%
Gross Margin: 0.00%
Operating Margin: -5007.02%
Profit Margin: 0.00%
Current Ratio: 10.89
Debt/Equity: 0.21
Total Debt: $48.54M
Free Cash Flow: $-77.67M
Revenue Growth: -53.90%
Earnings Growth: —
Enterprise Value: $19.53M

TRDA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$129.01M	$210.78M	$25.42M
Research & Development	$66.61M	$99.88M	$125.31M	$142.27M
Selling, General & Admin	$30.64M	$32.29M	$38.47M	$41.05M
Operating Expenses	$97.25M	$132.18M	$163.77M	$183.32M
Operating Income	-$97.25M	-$3.16M	$47.01M	-$157.90M
EBITDA	-$95.35M	-$321.00K	$50.78M	-$153.80M
Pretax Income	-$94.62M	$12.06M	$66.48M	-$142.83M
Income Tax	$0.00	$18.74M	$859.00K	$924.00K
Net Income	-$94.62M	-$6.68M	$65.63M	-$143.75M
Diluted EPS	-3.02	-0.20	1.68	-3.47
Diluted Shares	31.29M	33.05M	39.00M	41.37M

TRDA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$45.16M	$67.60M	$101.21M	$90.39M
Receivables	$0.00	$5.88M	$3.68M	$1.18M
Current Assets	$209.88M	$369.77M	$440.04M	$306.25M
Total Assets	$252.06M	$469.19M	$526.32M	$377.38M
Current Liabilities	$21.97M	$158.80M	$39.48M	$24.45M
Total Debt	$25.94M	$68.23M	$59.21M	$50.93M
Total Liabilities	$39.50M	$226.83M	$97.64M	$71.25M
Retained Earnings	-$188.28M	-$194.97M	-$129.34M	-$273.09M
Shareholders' Equity	$212.55M	$242.36M	$428.68M	$306.13M
Working Capital	$187.90M	$210.97M	$400.56M	$281.80M

TRDA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$93.79M	$139.80M	-$41.56M	-$128.51M
Capital Expenditure	-$2.89M	-$5.61M	-$3.16M	-$1.04M
Free Cash Flow	-$96.67M	$134.19M	-$44.72M	-$129.55M
Depreciation & Amortisation	$1.90M	$2.84M	$3.77M	$4.10M
Stock-Based Compensation	$9.89M	$13.11M	$17.91M	$19.61M
Investing Cash Flow	-$148.65M	-$138.40M	-$27.80M	$116.81M
Financing Cash Flow	$479.00K	$21.04M	$102.96M	$887.00K
Net Change in Cash	-$241.96M	$22.45M	$33.61M	-$10.82M

TRDA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$20.56M	$1.95M	$1.61M	$1.30M	$875.00K	$898.00K
Research & Development	$32.07M	$37.88M	$38.36M	$33.96M	$33.05M	$35.37M
Selling, General & Admin	$10.27M	$10.92M	$10.30M	$9.55M	$10.12M	$10.49M
Operating Expenses	$42.35M	$48.80M	$48.66M	$43.51M	$43.18M	$45.86M
Operating Income	-$21.79M	-$46.85M	-$47.05M	-$42.21M	-$42.30M	-$44.96M
EBITDA	-$20.84M	-$45.81M	-$45.82M	-$41.32M	-$41.50M	-$44.12M
Pretax Income	-$17.35M	-$42.92M	-$43.48M	-$39.07M	-$39.68M	-$42.73M
Income Tax	$0.00	$178.00K	$654.00K	$92.00K	$38.00K	$35.00K
Net Income	-$17.35M	-$43.10M	-$44.13M	-$39.16M	-$39.72M	-$42.76M
Diluted EPS	-0.42	-1.04	-1.06	-0.94	-0.95	-1.01
Diluted Shares	41.07M	41.34M	41.46M	41.60M	41.84M	42.22M

TRDA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$67.84M	$72.48M	$93.29M	$90.39M	$76.44M	$99.28M
Receivables	$2.04M	$1.18M	$1.20M	$1.18M	—	$816.00K
Current Assets	$403.19M	$369.15M	$338.26M	$306.25M	$266.87M	$232.70M
Total Assets	$486.48M	$448.78M	$412.90M	$377.38M	$335.52M	$298.88M
Current Liabilities	$18.43M	$19.80M	$24.02M	$24.45M	$19.20M	$21.37M
Total Debt	$57.00M	$54.74M	$52.40M	$50.93M	$49.75M	$48.54M
Total Liabilities	$69.22M	$69.28M	$72.18M	$71.25M	$64.66M	$65.47M
Retained Earnings	-$146.69M	-$189.80M	-$233.93M	-$273.09M	-$312.81M	-$355.57M
Shareholders' Equity	$417.26M	$379.50M	$340.72M	$306.13M	$270.60M	$233.41M
Working Capital	$384.76M	$349.34M	$314.24M	$281.80M	$247.68M	$211.33M

TRDA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$38.51M	-$29.49M	-$28.31M	-$32.20M	-$41.70M	-$32.46M
Capital Expenditure	-$1.14M	-$275.00K	—	—	-$44.00K	-$11.00K
Free Cash Flow	-$39.65M	-$29.76M	-$28.14M	-$32.00M	-$41.74M	-$32.47M
Depreciation & Amortisation	$946.00K	$1.03M	$1.23M	$886.00K	$805.00K	$841.00K
Stock-Based Compensation	$5.09M	$5.05M	$5.12M	$4.36M	$4.74M	$5.15M
Investing Cash Flow	$4.78M	$33.80M	$49.11M	$29.12M	$26.99M	$54.95M
Financing Cash Flow	$350.00K	$337.00K	$8.00K	$192.00K	$100.00K	$350.00K
Net Change in Cash	-$33.37M	$4.64M	$20.80M	-$2.89M	-$14.61M	$22.84M

Market Snapshot

About

Entrada Therapeutics is a clinical-stage biotechnology company developing intracellular therapeutics using its Endosomal Escape Vehicle (EEV) platform. The company focuses on treating diseases by enabling the delivery of therapeutic molecules into cells, targeting oncology and neuromuscular disorders. Entrada is advancing multiple programs through clinical trials to address significant unmet medical needs.